Enzon, Santaris deal
Santaris reacquired from Enzon rights, data, products and IP related to locked nucleic acid (LNA) platform to treat cancer after the companies mutually terminated their 2006 deal. Santaris said the program includes "several" compounds in clinical development and that Enzon will make an undisclosed payment to Santaris. Santaris said the move came after Enzon decided to cease its biotech activities. Earlier this year, Enzon said it will distribute the company's excess cash from ongoing royalty revenues to shareholders after the biotech concluded a review exploring the possible sale of the company or its assets. Enzon has no ongoing clinical development but receives royalties on seven products (see BioCentury, July 31, 2006 & April 29, 2013). ...